Der findes ingen informationer om sikkerhedsprofilen af Avastin hos patienter med kongenit hæmoragisk diatese, erhvervet koagulationsdefekt eller hos patienter, som modtager fuld dosis af antikoagulantia for behandling af tromboemboli før behandlingen med Avastin påbegyndes, da sådanne patienter ikke indgik i de kliniske studier.
There is no information on the safety profile of Avastin in patients with congenital bleeding diathesis, acquired coagulopathy or in patients receiving full dose of anticoagulants for the treatment of thromboembolism prior to starting Avastin treatment, as such patients were excluded from clinical trials.